Drug search by name

Reyataz (Atazanavir Capsules) and Liver disease

Result of checking the interaction of drug Reyataz (Atazanavir Capsules) and disease Liver disease for safety when used together.

Check result:

Reyataz (Atazanavir Capsules) <> Liver disease

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Patients with underlying hepatitis B or C viral infections or marked elevations in transaminases prior to atazanavir treatment may be at increased risk for developing further transaminase elevations or hepatic decompensation during use of atazanavir. In addition, atazanavir is primarily metabolized by the liver and may accumulate in patients with moderate or severe hepatic impairment. Therapy with atazanavir should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis. Atazanavir is not recommended for use in patients with severe hepatic impairment, and the combination of atazanavir/ritonavir is not recommended for patients with any degree of hepatic impairment.

References:

"Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.
Eholie SP, Lacombe K, Serfaty L, Wendum D, Girard PM "Acute hepatic cytolysis in an HIV-infected patient taking atazanavir." AIDS 18 (2004): 1610-1

Reyataz (Atazanavir Capsules)

Generic Name: atazanavir

Brand Name: Reyataz

Synonyms: Reyataz

What is Reyataz (Atazanavir Capsules)?